OncoMed Pharma (OMED) Reports Q2 Loss Per Share of 72c, Maintains FY Guidance

OncoMed Pharma (NASDAQ: OMED) reported Q2 EPS of ($0.72), may not comapre to the analyst estimate of ($0.49). Revenue for the quarter came in at $4.7 million versus the consensus estimate of $12.27 million.

2015 Full-Year Financial Guidance Reiterated

• 2015 full-year cash expenses are expected to total $100-$110 million, excluding non-cash stock-based compensation, depreciation, and amortization expenses
• OncoMed projects a 2015 year-end cash, cash equivalents and short-term investments balance of over $120 million, before considering the receipt of any potential collaboration milestones
• OncoMed could receive more than $150 million in milestone and option payments from partners during 2015 and 2016

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c